Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Wolverine Blend
Pre-mixed blend of BPC-157 and TB-500 (a synthetic Thymosin β4 fragment) in a single vial, marketed for tissue repair. This blend is not clinically validated; the evidence base is inferred from individual component peptides, both of which are grey-market research compounds with no FDA-approved human indications and no controlled human efficacy trials.
Mechanistic claims are extrapolated from preclinical (largely rodent) data on each component: BPC-157 has been reported to promote angiogenesis via VEGF/NO signaling, and TB-500 to promote actin polymerization and cell migration. Any additive or synergistic effect of the combination in humans has not been demonstrated in controlled trials.
No human efficacy trial has been published for this blend. The blend format is a vendor convenience (single reconstitution, single injection), not a clinically validated protocol. Component-level evidence is preclinical.
Typical Dose
5mg/5mg to 10mg/10mg per vial
Frequency
Daily to 2x/week
Route
SubQ
Notes
Standard sizes: 10mg (5/5) and 20mg (10/10). Lyophilized powder, reconstitute with bacteriostatic water. Store at 2-8°C.
Aggregated from 77 lab-verified Certificates of Analysis uploaded directly by 1 verified lab. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
COAs
77
Verified labs
1
Avg purity
99.58%
±0.28%
Endotoxin tested
64%
Tested by
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs